- Amarin expects its cash and cash equivalents to be approximately $135.4 million at the end of Q3 2014.
- Amarin appears to be on track to meet its 2014 cash outflow target, which was around $11 million better than I had calculated before.
- I had expected the difference to be made up by working capital changes, which appears likely to be the case.
- Vascepa sales growth is slower than anticipated though. Sales growth needs to improve to reach REDUCE-IT first read without additional funding or expense cutting.